5th International Conference on Accelerating Biopharmaceutical Development

March 12-15, 2017

We are very excited to announce the 5th edition of the International Conference on Accelerating Biopharmaceutical Development under the sponsorship of AIChE Society for Biological Engineering. This conference series is dedicated to strategies, technologies and capabilities that accelerate biopharmaceutical development. The conference is distinct in that it covers all aspects of biological process development bringing together senior thought leaders from across multiple disciplines.

For AccBio 2017, we are planning a four day conference that will again focus on reducing the time and cost of developing high quality biologic medicines. Session topics will include acceleration scenarios for promising drugs; development approaches for varied modalities and markets; ensuring delivery of quality product; leveraging prior knowledge to augment cost and timelines; and continuous/integrated process strategies. We hope these topics stimulate a robust discussion and exchange of ideas on how to more efficiently advance promising medicines to patients.

Please check back soon for updates on the conference program and the call for papers.

Conference Chairs

  • Dana Andersen, Genentech
  • Jeff Salm, Pfizer

Steering Committee

  • Tim Charlebois, Pfizer
  • Gene Schaefer, Janssen
  • Dean Pettit, Just Biotherapeutics
  • Morrey Atkinson, BMS
  • Aine Hanly, Amgen
  • Brian Kelley, Genentech
  • Charles Cooney, MIT
  • Chris Love, MIT
  • Nigel Titchener-Hooker, UCL
  • David Pollard, Merck
  • Hanne Bak, Regeneron
  • Jon Coffman, Boehringer-Ingelheim
  • Kelvin Lee, University of Delaware

Session Topics:

  • Trends, Volume Impact on Strategy
  • Acceleration Strategies
  • What is Quality?
  • Knowledge Management
  • Integration: What is the right balance of speed, cost and quality?



Featured Speakers

Atul Butte

Atul Butte, MD, PhD is the inaugural Director of the Institute of Computational Health Sciences (ICHS) at the University of California, San Francisco, and a Professor of Pediatrics.  Dr. Butte is also the Executive Director for Clinical Informatics across the six University of California Medical Schools and Medical Centers. Dr. Butte trained in Computer Science at Brown University, worked as a software engineer at Apple and Microsoft, received his MD at Brown University, trained in Pediatrics and Pediatric Endocrinology at Children's Hospital Boston, then...Read more

Reed J. Harris

Joined Genentech’s nascent process development Analytical Chemistry group in 1984, initially with protein chemistry and molecular characterization responsibilities for development products such as hGH (Protropin), tPA (Activase), tissue factor, soluble CD4, Xolair and Herceptin.  Identified many unexpected and/or novel protein modifications, which led to the good-natured “Dr. Doom” honorific awarded by project team colleagues.

   Global Xolair Genentech/Novartis CMC team leader from Phase II through the initial licensing stage, and leader of the team...Read more

Paul McKenzie

Paul McKenzie is the Executive Vice President of Pharmaceutical Operations & Technology at Biogen and has served in this position since July 2016. Dr. McKenzie is responsible for asset management, technical development, global manufacturing, supply chain operations, quality, and engineering He will also oversee construction and operation of Biogen’s advanced biologics manufacturing facility in Solothurn, Switzerland.

He joined the Company in February 2016, as Senior Vice President for Global Biologics Manufacturing...Read more